📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
84 announcements match the current filters (relevance ≥ 5).
Lupin Manufacturing Solutions & PolyPeptide Announce Strategic Alliance
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, has announced a strategic alliance with PolyPeptide Group AG to scale the global peptide supply chain. This collaboration aims to enhance supply chain resilience and improve operational efficiency. The partnership will focus on expanding sourcing options to meet rising global demand for peptide APIs. LMS has a team of 250+ scientists.
Key Highlights
Lupin Manufacturing Solutions (LMS) is a 100% subsidiary of Lupin Limited.
PolyPeptide runs a global network of six GMP-certified facilities.
LMS has a team of 250+ scientists.
PolyPeptide's shares are listed on SIX Swiss Exchange (SIX: PPGN).
👀 What to Watch
Investors should monitor the progress of this strategic alliance and its potential impact on Lupin's long-term growth in the peptide market. This partnership could strengthen Lupin's position as a CDMO supplier.
Lupin Receives Tentative U.S. FDA Approval for Siponimod Tablets
Lupin has received tentative approval from the U.S. FDA for Siponimod Tablets (0.25 mg, 1 mg and 2 mg), bioequivalent to Novartis' Mayzent®. These tablets are indicated for relapsing forms of multiple sclerosis. The product will be manufactured at Lupin’s Pithampur facility in India. Siponimod Tablets (RLD Mayzent®) had estimated annual sales of USD 195 million in the U.S. (IQVIA MAT October 2025).
Key Highlights
Received tentative U.S. FDA approval for Siponimod Tablets
Siponimod Tablets are bioequivalent to Mayzent® Tablets of Novartis
Indicated for treatment of relapsing forms of multiple sclerosis (MS)
Estimated annual sales of Siponimod Tablets (RLD Mayzent®) were USD 195 million in the U.S.
👀 What to Watch
This tentative approval is a positive sign for Lupin, potentially opening up a significant market opportunity. Investors should monitor the progress of the final approval and launch of this product.
Lupin Partners with Valorum for US Launch of Biosimilar Armlupeg™
Lupin Limited has entered into an exclusive licensing agreement with Valorum Biologics to commercialize its biosimilar Armlupeg™ (pegfilgrastim-unne) in the United States. Under the terms, Valorum will handle the commercialization and distribution, while Lupin remains responsible for the manufacturing and supply of the product. Lupin is entitled to receive an upfront license fee and recurring royalty payments on net sales. This partnership aims to capture market share in the U.S. oncology supportive care segment by providing affordable treatment options for chemotherapy patients.
Key Highlights
Exclusive licensing agreement with Valorum Biologics for biosimilar Armlupeg™ in the U.S. market.
Lupin to receive an upfront license fee and royalty payments on net sales of the biosimilar.
Lupin retains the manufacturing and supply mandate, ensuring utilization of its production facilities.
The product, Pegfilgrastim-unne, is used to reduce neutropenia incidence in patients undergoing chemotherapy.
Strategic move to strengthen Lupin's presence in the high-value U.S. biosimilars and specialty medicine market.
👀 What to Watch
Investors should view this as a positive development for Lupin's U.S. growth strategy, as it provides a clear path to monetization for its biosimilar pipeline through royalties. Monitor future quarterly earnings for the specific impact of the upfront fee and subsequent royalty income on the company's margins.
Lupin Gets U.S. FDA Approval for First Biosimilar Armlupeg™ Targeting $1.3 Billion Market
Lupin Limited has achieved a major milestone with the U.S. FDA approval of Armlupeg™, its first biosimilar for the U.S. market. The product is a biosimilar to Neulasta® (Pegfilgrastim) and targets a substantial market with estimated annual U.S. sales of USD 1,295 million as of September 2025. This approval validates Lupin's Pune-based biotech facility and its end-to-end biologic development capabilities. The company intends to leverage this approval to launch a broader portfolio of biosimilars in the coming years.
Key Highlights
Received U.S. FDA approval for Armlupeg™ (pegfilgrastim-unne) 6 mg/0.6 mL injection.
Targets the U.S. Pegfilgrastim market valued at approximately USD 1,295 million annually per IQVIA MAT Sept 2025.
Marks Lupin's first-ever biosimilar approval in the United States market.
Product will be manufactured at Lupin’s dedicated biotech facility in Pune, India.
Indicated for decreasing infection incidence in patients receiving myelosuppressive anti-cancer drugs.
👀 What to Watch
This approval is a significant positive trigger that de-risks Lupin's biotech pipeline and opens a high-value revenue stream. Investors should monitor the commercial launch and market share capture in the competitive U.S. biosimilar space.
